CardioBrief

One-stop source for cardiology news and links

  • Home
  • About

Live Blog: The FDA Advisory Panel On IMPROVE-IT

December 14, 2015 by Larry Husten 1 Comment

…

Click here to continue reading…

Filed Under: People, Places & Events, Policy & Ethics, Prevention, Epidemiology & Outcomes Tagged With: FDA, FDA advisory panel, IMPROVE-IT, live blog, Merck, vytorin, Zetia

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Recent Comments

  • Dr Waykup on What Can We Learn From The Apple Heart Study?
  • Y K Lau on Pioneering Cardiologist George Diamond Dead At 74
  • Ellie Kesselman on Right Wing Minority Rule
  • Jack frost on Conflicts of Interest in Cardiovascular Guidelines
  • Thomas Via on Amgen Requires Patients in Repatha Copay Program To Surrender Their Privacy

Archives

Note to Readers: A Time For Change

Click here to read about important new changes to CardioBrief.

Follow Cardiobrief on Twitter

Developed By: SKSDEV

CardioBrief Classics

Coca-Cola, The Olympic Torch, And The American College Of Cardiology
Stem Cell Therapy Company Hypes Preliminary Results
Good Science/Bad Science: Contrasting Papers On Dietary Compositon In JAMA And BMJ
Subway Meals Get American Heart Association Endorsement
This Week In Medicine: Stop Exercising and Eat Chocolate!
You Know Nothing, Dr. Snow: Why Medicine Can’t Be More Like Facebook
Politics and Transcatheter Aortic Valve Replacement
Half the News That’s Fit To Print: NY Times On ECG Screening For Student Athletes
New Perspective on the Dutch Cardiovascular Research Scandal
Mark Midei Can’t Get a Job Taking Blood Pressure At A Walmart
And the 2012 Award For the Most Dumbass Drug Promotion Goes To…
You Know Nothing, Dr. Snow: Why Medicine Can’t Be More Like Facebook
Politics and Transcatheter Aortic Valve Replacement
Half the News That’s Fit To Print: NY Times On ECG Screening For Student Athletes
Mark Midei Can’t Get a Job Taking Blood Pressure At A Walmart
Guest Post: More Lessons From the Riata ICD Lead Recall
Japanese Researcher With Harvard Connections Retracts 3 Articles in AHA Journals
Lancet Editor Richard Horton Tweets Dark View of Contemporary Medicine
Resveratrol and Fraud
Director of UConn CV Research Center Accused of Scientific Misconduct
2011 in Review: Rivaroxaban, Sapien, Mark Midei, Conflicts of Interest, and Much More
Nissen and Topol Clash Over Genetics and Personalized Medicine
Ray of Light for the Physician Payment Sunshine Act
Letter From Jail: A Cautionary Tale
One More Thought About Lipitor
Experts Clash Over Interpretation and Value of AIM-HIGH
Controversy Over Cholesterol Testing for Children
CardioBrief Poll: Should the ACC Train Industry Reps?
Daily Show Asks Why the AHA Killed a Bill Encouraging Healthy Behavior
National Lipid Association Expert Panel Has Many Deep Ties To Industry
Industry & Medicine: It’s Complicated
Easy Come, Easy Go? ESC To Review Dronedarone’s Role in AF Guidelines
The Pen Is Mightier Than the Scold
CNN Documentary Promises Screening and Vegan Diet Can Eliminate Heart Attacks
CNN, ABC, and NBC Dumb Down the News About CV Screening
US Senate Unanimously Endorses Campaign Against Atrial Fibrillation
Less May Be More, But Stents Are Neither Good Nor Bad
The Voice of the Patient: Time To Bring Out the Muzzle?
New Concerns Raised About Withdrawn Archives Meditation Paper
Archives Decides At Last Minute Not to Publish a Scheduled Paper
Part 2: The National Lipid Association And Industry
Part 1: The National Lipid Association and the FH Guidelines
Understanding Risk: Tricky Business
ACC CEO Jack Lewin Provides The Argument Against Industry Money
The ACC Counts Down To Launch Of New Satellites
Scientific Fraud Found In Wayne Alexander’s Research Group At Emory
$50K: The Price For A VIP Dinner For 2 With The Cleveland Clinic CEO
Evidence: The Weak Link Of Evidence-Based Medicine
Taking Medical Advice From Peggy Fleming?
The ACC Wants You To Know That Nothing Is Rotten In The State Of Maryland
An Embargo Becomes A Public Relations Tool
PROTECT II: Who Will Protect Us From The Protectors?
GRAVITAS Published: Who Gets To Weigh In On the Results?
WebMD: the 800 Pound Gorilla in the Room
Some Things Don’t Go Better With Coke
ACC and HRS Downplay Data From Their Own Registry
Dangling Doctors In Front of Journalists
Spinning Out of Control: Another Look at the PROTECT II Press Release
Questions Raised About Compensation and Conflicts at Duke
SHARP: A Tale of Two Press Releases
Will This Be the HDL Decade? REVEAL Revealed, Mixed Results for Apo-A1
CardioExchange at the AHA: A New Voice Emerges
Top New York City Interventional Cardiologists Now Making $3 Million a Year
The Plot Thickens in the Case of the Exploding ICD
Red light or green light for AAA screening?
Blue light special: AAA screening at Kmart in the disease-mongering aisle
The rise of the ESC: is the ESC anti-American or pro-industry?
Dronedarone and ticagrelor speed into ESC guidelines
The debate over CME and industry influence continues
Avandia aftermath: who are the winners and losers?
Debating medical promotion and education
Why is there a red dress on diet Coke cans?
SHAPE shifting: transforming guidelines into a business venture
Why was an Abbott marketing study published in the American Journal of Cardiology?
At the Dallas valve meeting even the faculty is for sale
A missing piece of the Multaq puzzle finally appears: DIONYSOS published to little fanfare
EHJ editors rebuffed GSK efforts to suppress Nissen editorial on rosiglitazone
“Is it safe?”
Why we shouldn’t kill all the lawyers just yet
Why is there a red dress on diet Coke cans?
Sunday at the AHA: ARBITER’s wild roller coaster ride in Orlando
Cardiology $$$: Mt Sinai’s Samin Sharma tops Columbia’s Moses
Residual Risk Reduction Initiative: promotion or education?
Editorial: the incompetence of the FDA
Editorial: SHAPE is skating on thin ice
Extreme cardiology culture: Califf, Harrington, Topol & Teirstein
October thought experiment: suppose the World Series were covered like the Nobel Prize
Live AF ablation broadcast on Today Show: what’s wrong with this picture?
More Multaq: Prystowsky whack-a-mole, ACC responds, Sanofi overtures to EPs
Pieces of a puzzle: Multaq, Sanofi, ACC, HRS, Prystowsky, AF Guidelines

Email Subscription

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 16,236 other subscribers

My Google Plus Profile

Archives

"I’d rather read Larry Husten on clinical trials than the constipated editorials in peer review journals." --Saurabh Jha (The Health Care Blog)

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

Return to top of page

Copyright © 2023 · Prose on Genesis Framework · WordPress · Log in